Skip Navigation

Surveillance may be suitable treatment option for patients with low-risk prostate cancer

18 June 2010

Active surveillance or watchful waiting might be sufficient treatment for patients with prostate cancer that has a low risk of progression, according to a new study published online on 18 June in The Journal of the National Cancer Institute.

Treatment of localized prostate cancer is controversial because, for some, this disease will not progress during their life time, and treatment may incur serious and long-lasting side effects. An increasingly popular option is active surveillance, or deferring treatment until evidence of disease progression.

Read the free article online here.

Read the free editorial online here.

Published in the Journal of the National Cancer Institute, Advance Access, 18 June 2010.

Read the full press release here.

For more information and contacts: JNCI press room


In the news

Business Week - 'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer